contralateral testicular cancer(English)

• including synchronous neoplasms, has been reported to occur in 2% to 4% of patients, with a 15-year actuarial risk of 2.4%. The overall excess risk compared with the general population was 40-fold. Patients treated with chemotherapy (primarily PVB) had a significantly reduced risk of a contralateral tumor, compared with those patients treated with radiation therapy or surgery alone, and that this risk reduction lasted for a period of at least 5 years. Thus, despite the potential for the reduction of risk of a CLTC by the use of chemotherapy, it must be assumed that all men with testicular cancer are at a small, but real, risk of a CLTC
• PVB
• Andrology, Oncology
• https://doi.org…-2865-7.00086-2